2013 EUROPEAN LEUKEMIANET RESPONSE CRITERIA VALIDATION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH 3 AVAILABLE TKIS OUTSIDE CLINICAL TRIALS

被引：0

作者：

Breccia, M. ^{[1
]}

Pregno, P. ^{[2
]}

Annunziata, M. ^{[3
]}

Orlandi, E. ^{[4
]}

Gozzini, A. ^{[5
]}

Iurlo, A. ^{[6
]}

Bocchia, M. ^{[7
]}

Franceschini, L. ^{[8
]}

Montefusco, E. ^{[9
]}

Crugnola, M. ^{[10
]}

La Nasa, G. ^{[11
]}

Scortechini, A. R. ^{[12
]}

Sgherza, N. ^{[13
]}

Sica, S. ^{[14
]}

Alimena, G. ^{[1
]}

Saglio, G. ^{[15
]}

Specchia, G. ^{[16
]}

机构：

[1] Univ Roma La Sapienza, Hematol, Dept Cellular Biotechnol & Hematol, Rome, Italy

[2] Citta Salute & Sci Torino AOU, Hematol, Turin, Italy

[3] Cardarelli Hosp, Hematol, Naples, Italy

[4] Fdn IRCSS Policlin San Matteo, Hematol, Pavia, Italy

[5] Careggi Hosp AOU, Hematol, Florence, Italy

[6] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Hematol, Milan, Italy

[7] Univ Siena, Hematol, Siena, Italy

[8] Univ Roma Tor Vergata, Rome, Italy

[9] S Andrea Hosp, Hematol, Rome, Italy

[10] Parma AOU, Hematol, Parma, Italy

[11] Univ Cagliari, Hematol, Dept Med Sci, Cagliari, Italy

[12] Osped Riuniti Ancona, Hematol, Ancona, Italy

[13] IRCSS Ist Tumori Giovanni Paolo II, Hematol, Bari, Italy

[14] Univ Cattolica, Hematol, Rome, Italy

[15] Univ Turin, Hematol, Turin, Italy

[16] Policlin Consorziale Bari AOU, Hematol, Bari, Italy

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PB1827

引用

页码：738 / 739

页数：2

共 50 条

[21] Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in the Long-Term Outcome of Patients With Early Chronic Myeloid Leukemia in Chronic Phase
Alvarado, Yesid
Kantarjian, Hagop
O'Brien, Susan
Faderl, Stefan
Borthakur, Gautam
Burger, Jan
Wierda, William
Garcia-Manero, Guillermo
Shan, Jianqin
Cortes, Jorge
CANCER, 2009, 115 (16) : 3709 - 3718
[22] Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events
Matteo Molica
Emilia Scalzulli
Gioia Colafigli
Danilo Alunni Fegatelli
Fulvio Massaro
Roberto Latagliata
Robin Foà
Massimo Breccia
Annals of Hematology, 2018, 97 : 1803 - 1808
[23] ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
Etienne, Gabriel
Dulucq, Stephanie
Lascaux, Axelle
Schmitt, Anna
Bidet, Audrey
Fort, Marie-Pierre
Lippert, Eric
Bureau, Caroline
Adiko, Didier
Hayette, Sandrine
Reiffers, Josy
Nicolini, Franck-Emmanuel
Mahon, Francois-Xavier
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (01) : 37 - 41
[24] Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)
Bataller, Alex
Garrido, Ana
Guijarro, Francesca
Diaz-Beya, Marina
Onate, Guadalupe
Hoyos, Montserrat
Arnan, Montserrat
Tormo, Mar
Vives, Susana
De Llano, Maria Paz Queipo
Salamero, Olga
Coll, Rosa
Gallardo, David
Vall-Llovera, Ferran
Escoda, Lourdes
Sampol, Antonia
Garcia-Guinon, Antonio
Merchan, Brayan
Bargay, Joan
Lopez-Guerra, Monica
Pratcorona, Marta
BLOOD, 2020, 136
[25] EUTOS LONG-TERM SURVIVAL SCORE (ELTS) BETTER DEFINES THE RISK OF DEATH FOR CHRONIC MYELOID LEUKEMIA PATIENTS TREATED OUTSIDE OF CLINICAL TRIALS
Molica, M.
Canichella, M.
Fegatelli, D. Alunni
Colafigli, G.
Massaro, F.
Latagliata, R.
Foa, R.
Breccia, M.
HAEMATOLOGICA, 2017, 102 : 83 - 83
[26] A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials
Felipe Casado, Luis
Maestro, Begona
Valentin Garcia-Gutierrez, J.
Helene Dumas, Marie
Massague, Isabel
Giraldo, Pilar
Perez-Encinas, Manuel
de Paz, Raquel
Martinez-Lopez, Joaqun
Bautista, Guiomar
Osorio, Santiago
Jose Requena, Maria
Palomera, Luis
Jesus Penarrubia, Maria
Calle, Carmen
Angel Hernandez-Rivas, Jose
Burgaleta, Carmen
Andrade, Marcio M., Sr.
Garcia-Ormena, Nuria
Luis Steegmann, Juan
BLOOD, 2012, 120 (21)
[27] Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
Malagola, Michele
Iurlo, Alessandra
Abruzzese, Elisabetta
Bonifacio, Massimiliano
Stagno, Fabio
Binotto, Gianni
D'Adda, Mariella
Lunghi, Monia
Crugnola, Monica
Ferrari, Maria Luisa
Lunghi, Francesca
Castagnetti, Fausto
Rosti, Gianantonio
Lemoli, Roberto M.
Sancetta, Rosaria
Coppi, Maria Rosaria
Corsetti, Maria Teresa
Cambrin, Giovanna Rege
Romano, Atelda
Tiribelli, Mario
Rossi, Antonella Russo
Russo, Sabina
Aprile, Lara
Bocchia, Monica
Gandolfi, Lisa
Farina, Mirko
Bernardi, Simona
Polverelli, Nicola
Roccaro, Aldo M.
De Vivo, Antonio
Baccarani, Michele
Russo, Domenico
CANCER MEDICINE, 2021, 10 (05): : 1726 - 1737
[28] Chronic Myeloid Leukemia: How Can Minimal Cytogenetic Response After 3 Months of Treatment Be Classified According to the New European LeukemiaNet Recommendations?
Jimenez-Velasco, Antonio
Barrios, Manuel
Alcala, Magdalena
Isabel Heiniger, Ana
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : E310 - E310
[29] The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution
Yilmaz, Musa
Kantarjian, Hagop M.
Jabbour, Elias J.
O'Brien, Susan M.
Borthakur, Gautam
Verstovsek, Srdan
Garcia-Manero, Guillermo
Ravandi, Farhad
Burger, Jan A.
Pierce, Sherry A.
Quintas-Cardama, Alfonso
Cortes, Jorge E.
BLOOD, 2012, 120 (21)
[30] Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in long-term outcome for patients (Pts) with chronic phase (CP) chronic myeloid leukemia (CML)
Alvarado, Yesid
Kantarjian, Hagop
Faderl, Stefan
Burger, Jan
Borthakur, Gautam
O'Brien, Susan
Wierda, William
Garcia-Manero, Guillermo
Cortes, Jorge
BLOOD, 2007, 110 (11) : 573A - 573A

← 1 2 3 4 5 →